Genscript Financial Statements From 2010 to 2024
| GNNSF Stock | USD 1.37 0.01 0.72% |
Check Genscript Biotech financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Genscript Biotech's main balance sheet or income statement drivers, such as , as well as many indicators such as . Genscript financial statements analysis is a perfect complement when working with Genscript Biotech Valuation or Volatility modules.
Genscript |
Genscript Biotech Company Profit Margin Analysis
Genscript Biotech's Profit Margin measures overall efficiency of a company and shows its ability to withstand competition as well as defend against adverse conditions such as rising costs, falling prices, decline in sales or management distress. Profit margin tells investors how well the company executes on its overall pricing strategies as well as how effective the company in controlling its costs.
Current Genscript Biotech Profit Margin | (0.66) % |
Most of Genscript Biotech's fundamental indicators, such as Profit Margin, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Genscript Biotech is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
In a nutshell, Profit Margin indicator shows the amount of money the company makes from total sales or revenue. It can provide a good insight into companies in the same sector, as well as help to identify trends of a company from year to year.
| Competition |
Based on the latest financial disclosure, Genscript Biotech has a Profit Margin of -0.6618%. This is 94.1% lower than that of the Healthcare sector and 97.13% lower than that of the Biotechnology industry. The profit margin for all United States stocks is 47.89% lower than that of the firm.
Genscript Biotech Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Genscript Biotech's current stock value. Our valuation model uses many indicators to compare Genscript Biotech value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Genscript Biotech competition to find correlations between indicators driving Genscript Biotech's intrinsic value. More Info.Genscript Biotech is one of the top stocks in return on equity category among its peers. It also is one of the top stocks in return on asset category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Genscript Biotech's earnings, one of the primary drivers of an investment's value.About Genscript Biotech Financial Statements
Genscript Biotech stakeholders use historical fundamental indicators, such as Genscript Biotech's revenue or net income, to determine how well the company is positioned to perform in the future. Although Genscript Biotech investors may analyze each financial statement separately, they are all interrelated. For example, changes in Genscript Biotech's assets and liabilities are reflected in the revenues and expenses on Genscript Biotech's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Genscript Biotech. Please read more on our technical analysis and fundamental analysis pages.
Genscript Biotech Corporation, an investment holding company, engages in the manufacture and sale of life science research products and services in North America, Europe, the Peoples Republic of China, Japan, the other Asia Pacific regions, and internationally. Genscript Biotech Corporation was founded in 2002 and is headquartered in Nanjing, the Peoples Republic of China. Genscript Biotech operates under Biotechnology classification in the United States and is traded on OTC Exchange. It employs 5573 people.
Currently Active Assets on Macroaxis
Other Information on Investing in Genscript Pink Sheet
Genscript Biotech financial ratios help investors to determine whether Genscript Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Genscript with respect to the benefits of owning Genscript Biotech security.